Rifaximin - Chitosan Nanoparticles for Inflammatory Bowel Disease (IBD)

Publisher： Bentham Science Publishers

E-ISSN： 2212-2710|11|1|41-52

ISSN： 1872-213X

Source： Recent Patents on Inflammation & Allergy Drug Discovery, Vol.11, Iss.1, 2017-08, pp. : 41-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Signaling Pathways Associated with Inflammatory Bowel Disease

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 4, Iss. 2, 2010-06 ,pp. : 105-117

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Hypoxia-Inducible Factor-1 (HIF-1) Signaling in Therapeutics: Implications for the Treatment of Inflammatory Bowel Disease

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 3, Iss. 1, 2009-01 ,pp. : 1-16

Bentham Science Publishers

Access to resources Recommend Favorite

The Study of Marketed and Experimental Formulation Approaches Enabling Site-specific Delivery of Mesalamine in Patients with Inflammatory Bowel Disease

By  

Recent Patents on Drug Delivery & Formulation, Vol. 8, Iss. 1, 2014-04 ,pp. : 3-11

Bentham Science Publishers

Access to resources Recommend Favorite

Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP

By  

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 3, Iss. 1, 2009-01 ,pp. : 69-75

Bentham Science Publishers

Access to resources Recommend Favorite

Inactivation of Pseudomonas aeruginosa by Chitosan Coated Iron Oxide Nanoparticles

By  

Recent Patents on Biotechnology, Vol. 10, Iss. 1, 2016-09 ,pp. : 133-139

Bentham Science Publishers

Access to resources Recommend Favorite